Business
Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
Announced two-trial clinical development strategy for AKY-2519 enabling evaluation in multiple patient segmentsInitiated Phase 1b clinical trial of AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC); expect preliminary data in 2027Announced AKY-2519 clinical imaging and dosimetry data presentation at upcoming 2026 ASCO Annual MeetingEnrolling patients with Nectin-4 expressing tumors in ongoing Phase 1b clinical trial of AKY-1189; expect preliminary data in first quarter 2027 BOS
About this update from Aktis Oncology, Inc.
[{"type":"image","alt":"Aktis Oncology Inc.","displaySize":"","headline":null,"caption":"Aktis Oncology Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/ce6b69e12b45a12fae0c8794865a1a20"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AR6yxKnk8scSucJfH1hgMg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMA--/https://media.zenfs.com/en/globenewswire.com/ce6b69e12b45a12fae0c8794865a1a20","width":300,"height":150},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/AR6yxKnk8scSucJfH1hgMg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMA--/https://media.zenfs.com/en/globenewswire.com/ce6b69e12b45a12fae0c8794865a1a20","width":300,"height":150}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Announced two-trial clinical development strategy for AKY-2519 enabling evaluation in multiple patient segments","length":111,"tagName":"p"}]},{"val":[{"type":"text","content":"Initiated Phase 1b clinical trial of AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC); expect preliminary data in 2027","length":137,"tagName":"p"}]},{"val":[{"type":"text","content":"Announced AKY-2519 clinical imaging and dosimetry data presentation at upcoming 2026 ASCO Annual Meeting","length":104,"tagName":"p"}]},{"val":[{"type":"text","content":"Enrolling patients with Nectin-4 expressing tumors in ongoing Phase 1b clinical trial of AKY-1189; expect preliminary data in first quarter 2027","length":144,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":496,"olType":false},{"type":"text","content":"BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today reported financial results and business highlights for the first quarter ended March 31, 2026.","length":402,"tagName":"p"},{"type":"text","content":""We continue to build momentum toward delivering a new class of radiopharmaceuticals targeting tumor types with large patient populations, leveraging our differentiated miniprotein radioconjugate platform and patient-first end-to-end supply chain,” said Matthew Roden, Ph.D., President and Chief Executive Offic...